<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778113</url>
  </required_header>
  <id_info>
    <org_study_id>16424</org_study_id>
    <secondary_id>I8R-MC-IGBD</secondary_id>
    <secondary_id>AMG 101</secondary_id>
    <secondary_id>GUO-P1-557</secondary_id>
    <nct_id>NCT02778113</nct_id>
  </id_info>
  <brief_title>A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults</brief_title>
  <official_title>A Single Site, Randomized, Four-Way, Four-Period PK/PD Crossover Phase 1 Clinical Study in 16 Fasted Healthy Adult Volunteers Receiving 3 Dose Levels of Intranasally Administered Glucagon and One Dose Level of Glucagon Administered by Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Locemia Solutions ULC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of LY900018. The
      study drug will be delivered into participant's nostril (intranasally) or will be given as an
      injection just under the skin (subcutaneously) once in each of four study periods. The study
      will last about 23 days for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Study Completion (Day 23)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve from Time Zero to the Last Quantifiable Concentration (AUC[0-t]) of Glucagon</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Glucagon</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Maximum Concentration (Tmax) of Glucagon</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Glucagon</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Area Under the Effect Concentration Time Curve (AUEC₀₋₄) of Blood Glucose (BG)</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Tmax of BG</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Cmax of BG</measure>
    <time_frame>Day 1 of each study period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY900018 - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900018 at dose level 1 administered once intranasally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900018 - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900018 at dose level 2 administered once intranasally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900018 - Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900018 at dose level 3 administered once intranasally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon - SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucagon administered once, SC, in one of four study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900018</intervention_name>
    <description>Administered intranasally.</description>
    <arm_group_label>LY900018 - Dose 1</arm_group_label>
    <arm_group_label>LY900018 - Dose 2</arm_group_label>
    <arm_group_label>LY900018 - Dose 3</arm_group_label>
    <other_name>AMG 504-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Glucagon - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) greater than or equal to 20.00 and below or equal to 28.00
             kg/m².

          -  Light-, non- or ex-smokers.

          -  Have no clinically significant diseases captured in the medical history or evidence of
             clinically significant findings on physical examination and/or clinical laboratory
             evaluations (hematology, biochemistry, ECG and urinalysis).

        Exclusion Criteria:

          -  Presence of any nose piercings.

          -  History of significant hypersensitivity to glucagon or any related products (including
             excipients of the formulations) as well as severe hypersensitivity reactions (like
             angioedema) to any drugs.

          -  Presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects.

          -  Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic or dermatologic disease.

          -  Presence of clinically significant findings on nasal examination and bilateral
             anterior rhinoscopy.

          -  Fasting blood glucose above 5.0 millimoles per liter (mmol/L) at screening, following
             a 12-hour fasting period.

          -  Fasting blood glucose assessed with a glucose meter above 5.5 mmol/L 0.5 hour before
             each dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

